Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis

• Published in: Vaccine Vol. 23; no. 28; pp. 3642 - 3648
• Main Authors: Khamesipour, Ali, Dowlati, Yahya, Asilian, Ali, Hashemi-Fesharki, Reza, Javadi, Amir, Noazin, Sassan, Modabber, Farrokh
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 25-05-2005; Elsevier; Elsevier Limited
• Subjects: Adult; Animals; Applied microbiology; Biological and medical sciences; Fundamental and applied biological sciences. Psychology; Good Manufacturing Practice; HIV; Human immunodeficiency virus; Human protozoal diseases; Humans; Infections; Infectious diseases; Iran; Leishmania; Leishmania major; Leishmania major - immunology; Leishmania major - pathogenicity; Leishmaniasis, Cutaneous - pathology; Leishmaniasis, Cutaneous - prevention & control; Leishmanization; Leshmaniasis; Live challenge; Male; Medical sciences; Mice; Mice, Inbred BALB C; Microbiology; Middle Aged; Parasites; Parasitic diseases; Protozoal diseases; Protozoan Vaccines - adverse effects; Protozoan Vaccines - immunology; Skin Tests; Studies; Tropical diseases; Vaccine; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vector-borne diseases; Virulence; Iran; Asia; Uzbekistan; Leishmanization; Vaccine; Iran; Live challenge; Leishmania; Infection; Kinetoplastida; Protozoa; Protozoal disease; Parasitosis; Leishmaniasis; Method
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2005.02.015

To establish the safety and reproducibility of live challenge with
Leishmania major, a single frozen stabilate was used in two open, single-arm leishmanization (LZ) trials. A total of 42 inoculations in 28 male adult volunteers were followed until complete healing.
Lesions induced by LZ are as diverse as natural infection, but much milder. Total protection was seen in 100% (11/11) of recovered volunteers. LZ used as live challenge to test vaccine candidates reduces the required sample size, is cost effective for surrogate markers studies and will induce protection in the participants who are not protected by candidate vaccines.